Current treatments in diabetic macular oedema: systematic review and meta-analysis

John Alexander Ford; Noemi Lois; Pamela Royle; Christine Clar; Deepson Shyangdan; Norman Waugh

doi:10.1136/bmjopen-2012-002269

Current treatments in diabetic macular oedema: systematic review and meta-analysis

John Alexander Ford
, Noemi Lois
, Pamela Royle
, Christine Clar
, Deepson Shyangdan
, Norman Waugh

Research output: Contribution to journal › Article › peer-review

96 Citations (Scopus)

Abstract

The aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse events

Original language	English
Article number	e002269
Journal	BMJ Open
Volume	3
Issue number	3
DOIs	https://doi.org/10.1136/bmjopen-2012-002269
Publication status	Published - 1 Mar 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1136/bmjopen-2012-002269

Cite this

@article{49ec23f33cbe4829a4c686b39f0e312e,

title = "Current treatments in diabetic macular oedema: systematic review and meta-analysis",

abstract = "The aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse events",

author = "Ford, \{John Alexander\} and Noemi Lois and Pamela Royle and Christine Clar and Deepson Shyangdan and Norman Waugh",

note = "This is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode. ",

year = "2013",

month = mar,

day = "1",

doi = "10.1136/bmjopen-2012-002269",

language = "English",

volume = "3",

journal = "BMJ Open",

issn = "2044-6055",

publisher = "BMJ Publishing Group",

number = "3",

}

TY - JOUR

T1 - Current treatments in diabetic macular oedema

T2 - systematic review and meta-analysis

AU - Ford, John Alexander

AU - Lois, Noemi

AU - Royle, Pamela

AU - Clar, Christine

AU - Shyangdan, Deepson

AU - Waugh, Norman

N1 - This is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

PY - 2013/3/1

Y1 - 2013/3/1

N2 - The aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse events

AB - The aim of this systematic review is to appraise the evidence for the use of anti-VEGF drugs and steroids in diabetic macular oedema (DMO) as assessed by change in best corrected visual acuity (BCVA), central macular thickness and adverse events

U2 - 10.1136/bmjopen-2012-002269

DO - 10.1136/bmjopen-2012-002269

M3 - Article

C2 - 23457327

SN - 2044-6055

VL - 3

JO - BMJ Open

JF - BMJ Open

IS - 3

M1 - e002269

ER -